SQZ Biotechnologies Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SQZ Biotechnologies Company
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
The industry has witnessed a lot of progress with cell therapies for blood cancers. The next critically important goal must be to find a safe and effective pathway for cell therapies in patients with solid tumors.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
- Site Specific
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- SQZ Biotech
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.